Lee Jia | Pharmacy | Research Excellence Award Published on 07/04/2026 by Invention Awards Prof. Lee Jia | Pharmacy | Research Excellence Award Distinguished Professor and Director in Henan University, United States Prof. Lee Jia is a highly accomplished pharmacologist with a strong academic foundation, earning his Ph.D. in Pharmacology from the State University of New York under Nobel Laureate Robert F. Furchgott and completing postdoctoral research at Duke University Medical Center in Durham, North Carolina. He currently serves as Distinguished Professor at The First Affiliated Hospital of Henan University and has held key leadership roles including Director of the Marine Drug R&D Center at Minjiang University and founding director of a cancer metastasis research center at Fuzhou University. His international career includes senior scientific positions at the National Cancer Institute, National Institutes of Health, and collaborations with institutions such as University of Geneva and Technological University Dublin. He is widely recognized for contributions to pharmacology, toxicology, nanomedicine, and cancer research, earning distinctions such as Fellow of the American Association of Pharmaceutical Scientists, Fellow of the Academy of Toxicological Sciences, and selection among the world’s top 2% scientists by Stanford University and Elsevier. He has received numerous prestigious honors including major national innovation awards in China, international research recognitions, and leadership roles in scientific societies such as the Chinese Pharmaceutical Association. In addition to his research impact, he has made extensive contributions as an editor, reviewer, and scientific organizer across leading journals and global conferences, shaping advancements in drug discovery and translational medicine. Citation Metrics (Scopus) 15000 12000 9000 6000 3000 100 0 Citations 13224 Documents 226 h-index 55 Citations Documents h-index View Scopus Profile Featured Publications Dual-site spatiotemporal and simultaneous inhibition on PIN1 via arsenic-retinoic albumin nanoparticles enables synergistic oncotherapy – Journal of Nanobiotechnology, 2026 Aptasensors and Advancement in Molecular Recognition Technology – Advanced Materials Technologies, 2025 Self-feeding multistage catalytic hairpin assembly programming supramolecular DNA nanoarchitecture for spatiotemporal molecular imaging of microRNA in living cells – Sensors and Actuators B: Chemical, 2025 Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers – Molecular Systems Biology, 2025 Structure-based discovery of forsythoside A as an effective inhibitor to reduce the neurotoxicity of amyloid β – Communications Chemistry, 2025
Jiankang Liu | Pharmacology | Research Excellence Award Published on 13/02/2026 by Invention Awards After Completing the Registration Process, your Biography will be displayed here. Register by using your Entry ID: 26048 Register Here
Nusret Erdogan | Toxicology and Pharmaceutical Science | Research Excellence Award Published on 10/02/202610/02/2026 by Invention Awards After Completing the Registration Process, your Biography will be displayed here. Register by using your Entry ID: 26022 Register Here
Hye Su Jeong | Pharmacoepidemiology | Research Excellence Award Published on 13/01/2026 by Invention Awards Dr. Hye Su Jeong | Pharmacoepidemiology | Research Excellence Award SK Bioscience, South Korea Dr. Hye Su Jeong is an epidemiologist and medical informatics specialist with a PhD from Korea University, where her research focused on signal detection of COVID-19 vaccine adverse events, following a master’s degree in Epidemiology and Health Informatics and a bachelor’s degree in Nursing. She is currently an RWE Specialist in Medical Affairs at SK bioscience, leading real-world evidence studies on vaccine safety, effectiveness, and healthcare utilization while supporting regulatory-aligned post-marketing research and cross-functional medical strategies. Previously, she served as a postdoctoral researcher under the BK21 L-HOPE Program, contributing to learning health system and smart health city research with international collaborations. Her extensive pharmacovigilance experience includes work as a nurse at the National Medical Center’s Drug Safety Monitoring Center, where she established and managed adverse event monitoring systems and conducted national-level vaccine and drug safety studies, including COVID-19 vaccines and remdesivir. Earlier, she worked as a Clinical Research Coordinator at Seoul National University Hospital, managing phase 2–4 clinical trials, multicenter studies, and regulatory audits. Dr. Jeong has presented widely at international conferences and has received multiple honors, including the Best Paper Award from the Korean Society for Pharmacoepidemiology and Risk Management and the Korea University Graduate School Excellent Thesis Award. Citation Metrics (Scopus) 12 10 8 6 4 2 0 Citations 12 Documents 6 h-index 2 Citations Documents h-index View Scopus Profile Featured Publications Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine (SKYCellflu® QIV) in Children and Adolescents: A Multicenter Test-Negative Case–Control Study in Korea – Vaccines, 2026 Efficacy of Digital Therapeutic Applications for Cognitive Training Among Older Adults with Mild Cognitive Impairment or Dementia: A Systematic Review and Network Meta-Analysis – Psychiatry Research, 2025 Public Opinion on Healthy Cities: Topic Modeling of South Korean News Articles (2004–2024) – Preprint, 2025 Bridging Smart Technologies and Healthy Cities: A Scoping Review Using WHO’s 6P Framework – Sustainable Cities and Society, 2024 Associations of Oseltamivir with Neuropsychiatric and Behavioral Adverse Events: A Systematic Review and Meta-Analysis – Review • Open Access
Dr. Hye Su Jeong | Pharmacoepidemiology | Research Excellence Award SK Bioscience, South Korea Dr. Hye Su Jeong is an epidemiologist and medical informatics specialist with a PhD from Korea University, where her research focused on signal detection of COVID-19 vaccine adverse events, following a master’s degree in Epidemiology and Health Informatics and a bachelor’s degree in Nursing. She is currently an RWE Specialist in Medical Affairs at SK bioscience, leading real-world evidence studies on vaccine safety, effectiveness, and healthcare utilization while supporting regulatory-aligned post-marketing research and cross-functional medical strategies. Previously, she served as a postdoctoral researcher under the BK21 L-HOPE Program, contributing to learning health system and smart health city research with international collaborations. Her extensive pharmacovigilance experience includes work as a nurse at the National Medical Center’s Drug Safety Monitoring Center, where she established and managed adverse event monitoring systems and conducted national-level vaccine and drug safety studies, including COVID-19 vaccines and remdesivir. Earlier, she worked as a Clinical Research Coordinator at Seoul National University Hospital, managing phase 2–4 clinical trials, multicenter studies, and regulatory audits. Dr. Jeong has presented widely at international conferences and has received multiple honors, including the Best Paper Award from the Korean Society for Pharmacoepidemiology and Risk Management and the Korea University Graduate School Excellent Thesis Award.
Dr. Hye Su Jeong | Pharmacoepidemiology | Research Excellence Award SK Bioscience, South Korea Dr. Hye Su Jeong is an epidemiologist and medical informatics specialist with a PhD from Korea University, where her research focused on signal detection of COVID-19 vaccine adverse events, following a master’s degree in Epidemiology and Health Informatics and a bachelor’s degree in Nursing. She is currently an RWE Specialist in Medical Affairs at SK bioscience, leading real-world evidence studies on vaccine safety, effectiveness, and healthcare utilization while supporting regulatory-aligned post-marketing research and cross-functional medical strategies. Previously, she served as a postdoctoral researcher under the BK21 L-HOPE Program, contributing to learning health system and smart health city research with international collaborations. Her extensive pharmacovigilance experience includes work as a nurse at the National Medical Center’s Drug Safety Monitoring Center, where she established and managed adverse event monitoring systems and conducted national-level vaccine and drug safety studies, including COVID-19 vaccines and remdesivir. Earlier, she worked as a Clinical Research Coordinator at Seoul National University Hospital, managing phase 2–4 clinical trials, multicenter studies, and regulatory audits. Dr. Jeong has presented widely at international conferences and has received multiple honors, including the Best Paper Award from the Korean Society for Pharmacoepidemiology and Risk Management and the Korea University Graduate School Excellent Thesis Award.